Nicox to co-promote eye drug with Bausch + Lomb in the US
PARIS Aug 8 (Reuters) - French pharmaceutical firm Nicox said it had notified Bausch + Lomb, a division of Valeant Pharmaceuticals, that it would exercise its option to co-promote eye drug latanoprostene bunod in the United States.
Nicox and B+L will now start negotiating a co-promotion agreement which will be signed at a later stage, Nicox said in a statement on Friday. (Reporting by Natalie Huet; Editing by Stephen Coates)
© Thomson Reuters 2017 All rights reserved.